All News

In part 3 of our interview, Jessica K. Paulus, ScD, Ontada, addresses the importance of understanding data sources and their impact on clinical research.

Bimekizumab demonstrated safety and efficacy at 2 years among patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).

Israeli patients with vitiligo exhibit a significantly reduced risk of developing Parkinson disease (PD).

New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis, but less severe reactions have been associated with ofatumumab.

Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.

The FDA approved SH-105 (Tepylute) prediluted injectable treatment for breast and ovarian cancers. This innovative formulation eliminates the need for complex powder reconstitution, improving safety and patient care.

Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers comprehensive patient-first care to those in the LGBTQ+ and gender diverse community.

High neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are associated with worse progression-free survival and 5-year overall survival in patients with ovarian cancer.

The announcement followed the release of the RhodoLED XL red light-emitting lamp, to be used in combination with aminolevulinic acid hydrochloride topical gel, 10% for actinic keratoses.

Heatwaves are causing unexpected surges in heat-related illnesses; the CDC recommends updated COVID-19 vaccines for all ages; prioritizing RSV vaccines for the highest-risk adults.

The field of sarcoma study is getting more specific, with clinical investigations drilling down to more specific subtypes of soft tissue sarcoma for better targeted therapies.

Test your knowledge of the June 2024 issue of AJMC with this quick quiz!

Results from a cross-sectional study revealed the gaps in knowledge related to fertility risks among patients with sickle cell disease (SCD), as well as shed light on patient perspectives on fertility treatments.

In April, the FDA approved decabtagene vicleucel (ide-cel) for earlier treatment of relapsed/refractory multiple myleoma.

However, registry data also showed no significant difference in transplant-free survival and time to pulmonary function decline between patients receiving antifibrotics vs placebo.

Of 7 subtypes identified 10,000 melanoma cells, C4 Melanoma COCO1A was the only to show indications of being more sensitive to natural killer (NK) and T cells.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib.

Different types of assays led to different results in measures of factor IX variant FIX-R338L, the authors found.

A new study highlights the potential of technology to aid in type 1 diabetes (T1D) management by balancing minimal user input with significant data output to improve user engagement and time in range.

This new report reveals that the US has made minimal progress in advancing health care equity over the past 2 decades.

Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score potentially identifying those at higher risk of recurrence.

A bidirectional risk between psoriasis and asthma has been identified, according to one study.

A study finds limited changes in hospice utilization, highlighting challenges in real-world implementation.

Jared Baeten, MD, PhD, discusses the significance of the PURPOSE 1 trial results, which found that lenacapavir for pre-exposure prophylaxis resulted in no new infections of HIV.

More than 80% of pregnant patients with new-onset hypertensive disorder remain hypertensive after hospital discharge.

Study findings provide new tools to assess treatment preferences when using hypomethylating agents in myelodysplastic syndromes (MDS).

Patients who used adjuvant chemotherapy were found to have a higher survival rate after achieving complete pathological response.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine explores the current treatment landscape of idiopathic hypersomnia and the associated challenges with approving new medication for this condition.

A 2-sample Mendelian randomization study found a potential connection between dietary intake and multiple sclerosis (MS) risk and severity.

The use of Plan B fell by 60% in states that implemented near-total abortion bans after Roe v. Wade was overturned; the Biden administration will impose inflation penalties on 64 prescription drugs in the third quarter of 2024; the FDA recently released draft guidance to ensure that drug companies and medical device makers enroll more women and people of color in clinical trials.